Dallas, TX -- (SBWire) -- 02/02/2011 -- Since Kalorama Information last updated our comprehensive market report on cancer testing, changes in the industry abound.
Developments that were novel two years ago such as the commercialization of service products , PGx testing and tissue microarrays are showing an increased presence. Some companies who promised much in the past have not produced results. And new entrants have entered the field.
These changes and more are addressed in Kalorama Information’s Worldwide Market for Cancer Diagnostics, 4th. Edition. This report authored by Kalorama Diagnostic Analyst Shara Rosen, contains detailed market data on the following IVD segments for their use in cancer diagnostics:
Histology/Cytology
Immunoassays
Flow Cytometry
Rapid Tests
Molecular Assays
Tissue Arrays
Circulating Tumor Cells
Pharmacodiagnostics
Buy Now : Market Research
http://www.reportsnreports.com/
Diagnostic tests for effective cancer screening are obviously needed more than ever. As cancer becomes more treatable, diagnostics are finding multiple expanded roles, including pharmacodiagnostics for matching the targeted treatment to the patient and ongoing disease monitoring as treatable cancer enters the realm of the chronic disease.
Kalorama Information’s Worldwide Market for Cancer Diagnostics, 4th Edition represents the fourth time Kalorama has engaged in an exhaustive study on the status of this important diagnostic market. Among the market data provided in this report, readers will find:
Immunoassay Lab Based Cancer Test Sales
Pap Smear Testing Volumes
World Cancer Statistics
POC Tests
DNA Reagents for Cancer Testing
CTC Testing Markets
Biochip Innovations
New Companies with Novel Approaches
“”Laggard”" Companies Who Have Not Met Expectations
Major Protein and Molecular Markers Used in Tissue Staining
Biomarkers Under Investigation
Acquisitions and Mergers
Status of PGx Testing
Microarray Markets in Clinical Labs
Lists of Vendors and Major Products
Unmet Needs of the Marketplace
This report includes market analysis of the following screening tests: The Cancer Profile, CTC, Fecal Occult Blood, PSA, H. pylori, IHC, ISH
As well as tests for specific cancers:
Bladder Cancer
Breast Cancer
Cervical Cancer
Colon Cancer
Lung Cancer
Ovarian Cancer
Prostate Cancer
This latest edition of Kalorama Information’s study takes a fresh look at all of these developments both qualitatively and quantitatively. The report provides revenue and growth forecasts through 2014 and, as in the previous edition, analyzes the market in two ways:
Tests for specific cancers, and Cancer tests in specific IVD segments
This allows the reader to match his or her own situation to the market at large.
In addition to extensive reviews of products on the market and in development in each segment, the report provides detailed company profiles.
Top Tier Companies
Abbott Diagnostics
Beckman Coulter Inc.
Becton, Dickinson and Company (BD)
bioMerieux Inc.
Bio-Rad Laboratories Inc.
Dako A/S
Fujirebio Diagnostics, Inc.
Gen-Probe Inc.
Hologic, Inc.
Inverness Medical Innovations
Ortho Clinical Diagnostics
QIAGEN N.V.
Roche Diagnostics
Siemens Medical Solutions Diagnostics
Sysmex Corporation
Status Quo Leader Companies
AdnaGen AG
Agendia BV
AMDL Diagnostics, Inc. (ADI)
American Diagnostica Inc.
Aperio Technologies, Inc.
Asuragen, Inc.
AviaraDx
Binding Site (The) Ltd.
BioCurex Inc.
BioGenex Laboratories, Inc.
BioImagene
Bio-Reference Laboratories, Inc.
Biotage AB
bioTheranostics
BioView Ltd.
Celera Diagnostics
China Medical Technologies, Inc.
Cisbio Bioassays
Clarient Inc. (formerly ChromaVision)
Clinical Data, Inc.
CytoCore, Inc.
DxS Ltd.
Epigenomics AG
Genetix Applied Imaging
Genomic Health, Inc.
Genzyme Genetics
Health Discovery Corporation
HistoRx, Inc.
Ikonisys, Inc.
Ipsogen SA
Lab21 Healthcare
Laboratory Corporation of America Holdings (LabCorp)
Life Technologies
Monogram Biosciences, Inc.
mtm laboratories AG
Myriad Genetics, Inc.
Nanosphere, Inc.
OncoVista Innovative Therapies, Inc.
Pathwork Diagnostics
Precision Therapeutics
Prometheus Laboratories Inc.
Quest Diagnostics
Response Genetics, Inc.
Rosetta Genomics Ltd.
Sequenom
Transgenomic Inc.
Veridex, LLC
Vermillion Inc.
Zila, Inc.
New Entrants
20/20 GeneSystems, Inc.
454 Life Sciences Corporation
Acrometrix Corporation (Life Tech.)
Acupath Laboratories, Inc.
Advalytix
Affymetrix, Inc.
Allegro Diagnostics
Althea Technologies, Inc.
Amorfix Life Sciences Ltd.
Arbor Vita Corporation
ArcticDx Inc.
Arrayit Diagnostics Inc.
AVEO Pharmaceuticals, Inc.
Axela, Inc.
Baypoint Biosystems, Inc.
Biodesix, Inc.
Biologix Diagnostics, LLC
BioMarker Strategies, LLC
Biomoda
BioMosaics
BioProspecting NB, Inc. (BPNBI)
BioServe
Biosystems International SAS (BSI)
BioTrove, Inc.
Cambridge Research & Instrumentation, Inc. (CRi)
Cangen Biotechnologies, Inc.
Caris Diagnostics
Castle Biosciences Inc.
Celerus Diagnostics
Cell Biosciences
CeMines, Inc.
Cepheid
ChromoCure Inc.
Chronix Biomedical Inc.
Clinical Genomics Pty Ltd.
CombiMatrix Molecular Diagnostics (CMDX)
Comprehensive Cancer Cell (CCC) Diagnostics Inc.
Compugen Ltd.
Correlogic Systems, Inc.
CS-Keys, Inc.
deCode Genetics Inc.
DiaGenic ASA
DiagnoCure –
Diagnoplex
Diagnostic Biosystems Company
DNA Direct, Inc.
DexTerity Diagnostics
EDP Biotech Corporation
Epistem Plc
Exact Sciences Corp.
Exiqon A/S
ExonHit Therapeutics
Exosome Diagnostics Inc.
Expression Pathology Inc.
Falcon Genomics, Inc.
FASgen Diagnostics, LLC
Fluxion Biosciences
Foligo Therapeutics, Inc.
Gastrocor
Genelex Corporation
GeneNews Limited
Genoptix
iKaryos Diagnostics
Illumina
Inostics GmbH
InteRNA Technologies B.V.
Intrinsic Bioprobes Inc.
Invirion Diagnostics, LLC
InVivoScribe Technologies
Iris BioTechnologies Inc.
IRIS International, Inc.
MabCure Inc.
MacroArray Technologies, LLC
MagArray Inc.
Martell Biosystems, Inc.
Med BioGene, Inc. (MBI)
Medical Prognosis Institute
Metabolon, Inc.
Miraculins Inc.
MolecularMD Corp.
Neogenix Oncology, Inc.
NextGen Sciences
Nuvera Biosciences
Olink AB
Oncimmune LLC
OncoMethylome Sciences S.A.
On-Q-ity
Orion Genomics
Oxford BioTherapeutics
Pacific Edge Biotechnology Ltd. (PEB)
Photocure ASA
Power3 Medical Products, Inc.
Prediction Sciences
Predictive Biosciences
PrognosDx Health, Inc.
Provista Life Sciences LLC
Rubicon Genomics, Inc.
Rules-Based Medicine, Inc. (RBM)
Saladax Biomedical, Inc. (SBI)
SensiGen LLC
Sienna Cancer Diagnostics
Signature Genomic Laboratories, LLC
Singulex Inc.
Skyline Diagnostics B.V.
Source MDx
Soar BioDynamics, Ltd.
Strategic Diagnostics Inc.
Synergenz Bioscience Ltd.
Targeted Molecular Diagnostics (TMD)
Theranostics Health (TH)
TrimGen Corporation
TrovaGene, Inc.
Vitatex Inc.
WaferGen Biosystems, Inc.
Xceed Molecular (formerly MetriGenix Corporation)
Zetiq Technologies Ltd.
The various diagnostic techniques and trends are discussed from the point of view of their present and potential market impact.
Therefore, the report does not provide an in depth discussion of the etiology, physiology and clinical manifestations of cancer except where an understanding of these areas is required to understand the impact that new and early diagnostics exert on patient care. Similarly, the report does not describe the technical aspects of the test modalities, for example
All market data is based on factory sales to the end user and not retail pricing or reimbursement payments. For cancer testing, this means that the actual dollar market – that is what manufacturers earn from the sale of their products is undervalued. This is because many of the new tests are offered as test services either by the companies that have developed the tests and/or their partners.
Market data is presented in dollar market size for categories of tests, and for specific analytes where possible. Here the dollar value of a market segment is directly proportional to the number of tests performed, because the cost of the instrumentation is generally buried in the per test price.
The report discusses tests and technologies that are currently available and those that are expected to take their place. Generally, current products and technologies establish the standard of care and its value to payers. Many of the assays and imaging techniques presented in the report are expected to replace the standard of care in 2010, but with healthcare systems’ emphasis on cost/benefit analysis for new technologies adoption, the market value and thus penetration capabilities of newer approaches may be limited.
The information presented in this report is derived on publicly available information sources such as company, government, and medical organization reports. The analysis is based on the author’s industry knowledge combined with literature searches and interviews with industry professionals and experts in the areas of in vitro diagnostics, imaging industries and cancer specialists.
Related Reports
Women’s Health: Worldwide Prescription Drug Markets, 4th Edition
http://www.reportsnreports.com/reports/182-womens-health-worldwide-prescription-drug-markets-4th-edition.html
Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis, 4th Edition
http://www.reportsnreports.com/reports/33665-emerging-cancer-vaccines-forecasts-developments-and-pipeline-an.html
Worldwide Market for In Vitro Diagnostic Tests, 7th Edition
http://www.reportsnreports.com/reports/26641-worldwide-market-for-in-vitro-diagnostic-tests-7th-edition-the.html
About ReportsnReports
ReportsnReports comprises of an online library of 50,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts of almost all well-known publishers of such reports across the globe. We, as a third party reseller of market research reports employ number of marketing tools such as press releases, email-marketing and effective search engine optimization technique to drive revenues for our clients.
Worldwide Market for Cancer Diagnostics 4th Edition